Lipocine's partner Verity Pharma files New Drug Submission for TLANDO in Canada

Lipocine Inc.

Over 700,000 annual TRT prescriptions in Canada, representing large opportunity.
TLANDO is the first US FDA-approved oral TRT without dose titration.
Exclusive license with Verity signed Jan 2024; NDS covers Canada.
CEO Mahesh Patel says if approved, TLANDO could drive significant market gains.
About 50% of Canadian TRT patients have private insurance coverage.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.